Is There a Generic Version of Biktarvy Available in 2026?
No, no generic version of Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) will be available in 2026. Gilead Sciences holds multiple patents protecting the drug until at least 2031-2033, with no FDA-approved generics or tentative approvals listed as of now.[1][2]
When Do Biktarvy Patents Expire?
Key U.S. patents on Biktarvy's combination expire between 2031 and 2033:
- Bictegravir (core component): Patent 9,539,242 expires December 2031.
- Fixed-dose combination: Patents like 10,016,401 extend to March 2033.
- Pediatric exclusivity may push effective market entry to 2034.
Full patent details and litigation updates are tracked on DrugPatentWatch.com.3
Why No Generics Until Then?
Gilead has settled major Paragraph IV challenges with generics makers like Aurobindo, MSN, and Viatris. These agreements delay U.S. entry until 2032 at the earliest (2031 for most, with one to 2036), barring successful court challenges. No ANDA has been approved, and FDA's Orange Book lists zero generics.[1][2]3
What About Biosimilars or Other Versions?
Biktarvy is a small-molecule fixed-dose combo, so it faces generics, not biosimilars. Interchangeable copies require proving bioequivalence, but patent walls block approval. No tentative ANDAs signal imminent entry.3
When Could Generics Actually Launch?
Earliest realistic U.S. launch is mid-2032 after settlements, assuming no further extensions or losses in ongoing suits (e.g., Gilead vs. generics challengers). In Europe, some generics may enter earlier via EMA approvals around 2029-2030, but U.S. lags due to stronger patent enforcement.3
How Does This Compare to Other HIV Drugs?
Unlike Truvada (generics since 2020 post-patent expiry), Biktarvy's newer formulation and combo patents extend protection. Competitors like Dovato or Cabenuva face similar delays, keeping Gilead dominant until early 2030s.[1]
Sources
[1]: FDA Orange Book (accessdata.fda.gov/scripts/cder/ob/)
[2]: Gilead Investor Updates (gilead.com)